13th Annual VBWG Global Chapter Meeting
Prior to AHA Scientific Sessions
Date: Saturday, November 3
Location: Rosen Shingle Creek Hotel, Orlando, Florida
If you plan to attend the AHA Scientific Sessions, please join Carl J. Pepine, MD, MACC, and VBWG members for an exciting review, exchange, and assimilation of new data from vascular biology research.
| Agenda |
|
|
|
|
| 1:00–1:10 PM |
|
Welcome and Opening Remarks |
|
Chair:
Carl J. Pepine, MD, MACC
University of Florida College of Medicine
Gainesville, Florida
Co-Chair:
Roberto Ferrari, MD, PhD, FACC, FESC
Azienda Ospedaliera-Universitaria di Ferrara
Ferrara, Italy
|
| 1:10–1:15 |
|
Cardiology Fellows Research Grant Winners |
|
CME Coordinator:
Eileen M. Handberg, PhD, ARNP-BC
University of Florida College of Medicine
Gainesville, Florida |
Session I: Chronic Coronary Syndromes and Intervention |
1:15–1:25 |
|
New Thoughts on Optimal Medical Therapy and Risk Stratification |
|
William S. Weintraub, MD, FACC
Christiana Care Health System
Newark, Delaware |
1:25–1:35 |
|
PCI: State of the Art |
|
Spencer B. King III, MD, MACC, FACP, FESC, FSCAI
Emory University School of Medicine
Atlanta, Georgia |
1:35–1:45 |
|
MSCs for Post MI Treatment |
|
Joshua M. Hare, MD
University of Miami
Miller School of Medicine
Miami, Florida |
1:45–1:55 |
|
Intramyocardial Transplantation of CD34+ Stem Cells for Intractable Angina: New Trial Data |
|
Douglas W. Losordo, MD
Northwestern University
Feinberg School of Medicine
Chicago, Illinois |
1:55–2:05 |
|
PPAR Modulation and Endothelial Progenitor Cell Regeneration |
|
Helmut Drexler, MD
Medizinische Hochschule Hannover
Hannover, Germany |
| 2:05–2:20 |
|
Group Discussion |
|
|
Session II: Cardiometabolic Risk |
2:20–2:30 |
|
PPARs and CV-Renal Risk: New Data and Insights |
|
Jeffrey L. Probstfield, MD, FACC, FACP, FAHA, FESC
University of Washington School of Medicine
Seattle, Washington |
2:30–2:40 |
|
Preventing Hyperglycemia-Induced Endothelial Dysfunction and Oxidative Stress: Genetic Insights |
|
Thomas F. Lüscher, MD, FRCP
University Hospital Zurich
Zurich, Switzerland |
2:40–2:50 |
|
Improvement of Heart Function with Glucagon-Like Peptide-1 Infusion: New Data |
|
Richard P. Shannon, MD
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania
|
2:50–3:00 |
|
Vascular Effects of HDL: Ongoing Debate and Controversy |
|
Mohamad Navab, PhD
David Geffen School of Medicine at UCLA
Los Angeles, California
|
| 3:00–3:315 |
|
Group Discussion |
|
|
Session III: Risk Stratification for CAD |
3:15–3:25 |
|
Recent Advances in Risk Prediction Using Coronary Calcification |
|
Roger S. Blumenthal, MD, FACC
Johns Hopkins University School of Medicine
Baltimore, Maryland |
3:25–3:35 |
|
Potential Role of New Genetic Markers in Predicting MI |
|
Robert Roberts, MD, FRCPC, MACC
University of Ottawa Heart Institute
Ottawa, Ontario, Canada |
3:35–3:45 |
|
Place of IMT in Risk Stratification |
|
Allen J. Taylor, MD, FACC, FAHA
Walter Reed Army Medical Center
Washington, DC |
| 3:45–3:55 |
|
Group Discussion |
|
|
Session IV: New Targets and Trials in Vascular Biology |
3:55–4:05 |
|
Genetic Factors Influencing Resistance to Antiplatelet Agents |
|
Jane E. Freedman, MD
Boston University School of Medicine
Boston, Massachusetts |
4:05–4:15 |
|
Expectations from the ONTARGET Trial |
|
Salim Yusuf, MD, DPhil, FRCPC, FRSC
McMaster University
Hamilton, Ontario, Canada |
4:15–4:25 |
|
Targeting Renin Inhibition for Pharmacotherapy |
|
Suzanne Oparil, MD
The University of Alabama at Birmingham
Birmingham, Alabama |
4:25–4:35 |
|
The If Current: New Therapeutic Target for Cardiovascular Disease |
|
Roberto Ferrari, MD, PhD, FACC, FESC
Azienda Ospedaliera-Universitaria di Ferrara
Ferrara, Italy |
4:35–4:45 |
|
New Mechanistic and Clinical Data from MERLIN |
|
Benjamin M. Scirica, MD, MPH
Harvard Medical School
Boston, Massachusetts |
| 4:45–5:00 PM |
|
Group Discussion |
|
|
5:00 |
|
Adjourn |
|
|
Click here to register or contact MEDCON at 1.866.557.9090 for more information
This meeting is sponsored by the University of Florida College of Medicine Continuing Medical Education.
Accreditation
The University of Florida College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.
Credit
The University of Florida College of Medicine designates this educational activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Funding for this meeting is made possible through the generous support of the Foundation Sponsors of the Vascular Biology Working Group: AstraZeneca, Boehringer Ingelheim, CV Therapeutics Inc, and Pfizer Inc.
|
Options